Introduction: There is increasing interest in the potential for psychedelic drugs such as
psilocybin, LSD and ketamine to treat several mental health disorders, with a growing …

Modern psychedelic research remains in an early phase, and the eventual introduction of
psychedelics into clinical practice remains in doubt. In this piece, we discuss the role of …

Background: The classical psychedelics, psilocybin, peyote, ayahuasca/N, N-
dimethyltryptamine, and lysergic acid diethylamide are considered promising new …

Rationale Psychedelic research continues to garner significant public and scientific interest
with a growing number of clinical studies examining a wide range of conditions and …

Results: In total, 126 articles were included, encompassing 86 unique studies. Of studies
with a drug control condition (80), 49 (61.2%) used an inert placebo control, 16 (20.0%) …

Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers
and lingering questions about study design, such as the difficulty of ensuring adequate …

Research in the last decade has expressed considerable optimism about the clinical
potential of psychedelics for the treatment of mental disorders. This optimism is reflected in …

Favourable regulatory assessments, liberal policy changes, new research centres and
substantial commercial investment signal that psychedelic therapy is making a major …

With the extensive public, commercial and scientific interest from what has been widely
termed the psychedelic renaissance, it is important that the scientific practices and results …

Responses to psychedelics are notoriously difficult to predict, yet significant work is currently
underway to assess their therapeutic potential and the level of interest in psychedelics …